Scienmag
SEPTEMBER 27, 2020
New study based on the early versus late intervention trial with estradiol data confirms benefit of hormone therapy in reducing multiple biomarkers of inflammation CLEVELAND, Ohio (September 28, 2020)–As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health (..)
Drug Discovery World
APRIL 5, 2024
Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). The preclinical data for COR-1167 is very promising and we are excited to determine its therapeutic potential in patients.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
DECEMBER 29, 2020
Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. Audentes Therapeutics’ ASPIRO Trial Free to Proceed. The ASPIRO trial is a two-part, open-label ascending dose study, and is examining the safety and preliminary efficacy of AT132 in children with XLMTM younger than five years old.
The Pharma Data
FEBRUARY 21, 2022
Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.
XTalks
NOVEMBER 19, 2021
Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.
XTalks
FEBRUARY 8, 2024
According to AstraZeneca, the drug had strong demand across all of its approved indications and was further supported by recent guideline updates from cardiology societies. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials. billion ($657 million).
XTalks
AUGUST 2, 2023
5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.
Expert insights. Personalized for you.
46 
Let's personalize your content